Thrombosis Drugs Market Forecast up to 2024

Thrombosis Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024

Overview:

Thrombosis refers to the medical term used for the development of blood clot within a blood vessel. The condition occurs when a blood clot forms and blocks an artery or a vein, stopping or blocking the flow of blood. Thrombosis drugs are used to treat or prevent the formation of blood clot, which can cause diverse thrombotic events. The drugs for the treatment of thrombosis include anticoagulants and thrombin inhibitor drugs. These drugs reduce the clotting power of the blood, and subsequently the probabilities of the disease events. The various disease conditions treated with thrombosis drugs include deep vein thrombosis (DVT), pulmonary embolism, and atrial fibrillation. According to the estimation of Thrombosis UK, every 6 seconds an individual dies from VTE globally, that is 1 in 4 people die due to reasons related to blood clots. According to the estimation of Centers for Disease Control and Prevention, there are around 900,000 people afflicted by DVT or pulmonary embolism; also, 1 or 2 per 1,000 individuals each year are affected in the US.
The market for thrombosis drugs is driven by an upsurge in the burden of cardiovascular disease & trauma cases and increasing geriatric & obese population. The increase in the launch of novel drugs in the market and research activities to develop innovative drugs provide an opportunity for enhanced and effective treatment, which is expected to support the market growth in the next five years. However, side effects allied with thrombosis drugs and less awareness among the public about thromboembolism conditions may slow down the growth of the market.

Market Analysis: The “global thrombosis drugs market” is estimated to witness a CAGR of 9.5% during the forecast period 2018–2024. The market is analyzed based on three segments – drug class, indication, and regions.

Drug Class Analysis: The thrombosis drugs market by drug class is segmented into factor Xa inhibitor, low molecular weight heparin, and P2Y12 platelet inhibitor. The factor Xa inhibitor segment occupied a significant market share in 2017 and is expected to grow at a high CAGR during the forecast period. The high preference of anticoagulant drug usage is expected to boost the segment growth during the forecast period.

Indication Analysis: The thrombosis drugs market by indication is segmented into pulmonary embolism, atrial fibrillation, and deep vein thrombosis. The pulmonary embolism segment occupied a significant share in 2017 and is anticipated to grow at a high CAGR during the forecast period. Increasing focus on the development of low-cost drugs and large patient pool with pulmonary embolism condition are likely to propel the market growth in the next five years.

Region Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global thrombosis drugs market, followed by Europe. The availability of novel anticoagulants, the presence of dominant market players, increased disease awareness, and rising healthcare expenditure make North America a dominant shareholder in the market. Asia Pacific is the fastest growing region due to an upsurge in the prevalence of cardiovascular disease & other age-related chronic diseases, growing healthcare expenditure, and increasing access to healthcare services.

Key Players:Johnson & Johnson, Aspen Pharmacare Holdings, Sanofi S.A., Bayer AG, Boehringer Ingelheim, and Bristol–Myers Squibb are the key players in the market. Few of the predominate players in the market include AstraZeneca plc, Daiichi Sankyo, Pfizer, Inc., and Baxter International Inc.

Competitive Analysis:Due to the increasing demand for thrombosis drugs in recent years, many companies are collaborating to develop novel drugs, and new thrombosis drugs have been launched and approved globally. For instance, in December 2017, Aurobindo Pharma received FDA approval to manufacture and market its generic version of Fondaparinux Sodium injection used to prevent DVT. Janssen Pharmaceuticals, in late 2017, announced the launch of XARELTO (rivaroxaban) for reducing the sustained risk of recurrent venous thromboembolism (VTE). In June 2017, Portola launched its drug betrixaban (Bevyxxa) in the US market. In June 2018, Biogen entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007, a plasminogen inhibitor and backup compounds.
Benefits: The report provides complete details about the products offered by thrombosis drugs companies in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Table of Contents

1 Industry Outlook 9
1.1 Industry Overview 9
1.1.1 Global Drivers for Pharmaceutical Demand 10
1.1.2 R&D Pipeline in the Pharmaceutical Industry 10
1.2 Industry Trends 14
2 Report Outline 15
2.1 Report Scope 15
2.2 Report Summary 15
2.3 Research Methodology 16
2.4 Report Assumptions 16
3 Market Snapshot 18
3.1 Market Definition – Infoholic Research 18
3.2 Causes of Thrombosis 18
3.3 Risk Factors for Thrombosis 18
3.4 Symptoms of Thrombosis 19
3.5 Diagnosis of Thrombosis 19
3.6 Segmented Addressable Market 19
3.7 Trends in the Thrombosis Drugs Market 20
3.8 Related Markets 21
3.8.1 Over-the-Counter (OTC) Drugs 21
3.8.2 Cardiovascular Drugs 22
3.8.3 Respiratory Drugs 23
4 Market Outlook 24
4.1 Market Segmentation 24
4.2 PEST Analysis 24
4.3 Porter 5(Five) Forces 25
5 Market Characteristics 27
5.1 DRO Analysis – Market Dynamics 27
5.1.1 Drivers 27
5.1.1.1 Increasing burden of cardiovascular disease and trauma cases 27
5.1.1.2 Upsurge in the geriatric and obese population 28
5.1.2 Opportunities 28
5.1.2.1 Increase in health care spending and demand for better treatment in emerging economies 28
5.1.2.2 Increasing new product launch and R&D activities 29
5.1.3 Restraints 29
5.1.3.1 Side effects associated with thrombosis drugs 29
5.1.3.2 Lack of awareness about thromboembolism conditions 29
5.2 DRO – Impact Analysis 30
5.3 Key Stakeholders 31
6 Drug Class: Market Size and Analysis 33
6.1 Overview 33
6.2 Factor Xa Inhibitors 34
6.3 Low Molecular Weight Heparin 35
6.4 P2Y12 Platelet Inhibitors 36
7 Indication: Market Size and Analysis 38
7.1 Overview 38
7.2 Deep Vein Thrombosis 38
7.3 Pulmonary Embolism 39
7.4 Atrial Fibrillation 39
8 Regions: Market Size and Analysis 40
8.1 Overview 40
8.2 North America 41
8.3 Europe 43
8.4 Asia Pacific 44
8.5 Rest of the World 45
9 Competitive Landscape 47
9.1 Overview 47
10 Vendors Profile 49
10.1 Aspen Pharmacare Holdings Limited 49
10.1.1 Overview 49
10.1.2 Business Units 50
10.1.3 Geographic Presence 51
10.1.4 Business Focus 52
10.1.5 SWOT Analysis 52
10.1.6 Business Strategies 53
10.2 Johnson & Johnson 53
10.2.1 Overview 53
10.2.2 Business Units 57
10.2.3 Geographic Presence 58
10.2.4 Business Focus 59
10.2.5 SWOT Analysis 60
10.2.6 Business Strategies 60
10.3 Sanofi S.A. 61
10.3.1 Overview 61
10.3.2 Business Units 64
10.3.3 Geographic Presence 65
10.3.4 Business Focus 66
10.3.5 SWOT Analysis 66
10.3.6 Business Strategies 66
10.4 Boehringer Ingelheim GmbH 67
10.4.1 Overview 67
10.4.2 Business Units 69
10.4.3 Geographic Presence 70
10.4.4 Business Focus 71
10.4.5 SWOT Analysis 71
10.4.6 Business Strategies 72
10.5 Bayer AG 72
10.5.1 Overview 72
10.5.2 Business Units 75
10.5.3 Geographic Presence 76
10.5.4 Business Focus 77
10.5.5 SWOT Analysis 77
10.5.6 Business Strategies 78
10.6 Bristol–Myers Squibb 78
10.6.1 Overview 78
10.6.2 Business Units 82
10.6.3 Geographic Presence 83
10.6.4 Business Focus 83
10.6.5 SWOT Analysis 83
10.6.6 Business Strategies 84
11 Companies to Watch For 85
11.1 AstraZeneca PLC 85
11.1.1 Overview 85
11.2 Pfizer Inc. 87
11.2.1 Overview 87
11.3 Baxter International Inc. 89
11.3.1 Overview 89
11.4 Daiichi Sankyo 91
11.4.1 Overview 91
Annexure 93
Abbreviations 93

List  of  Tables

TABLE 1 REGION-WISE PHARMACEUTICAL SPENDING ($MILLION) 10
TABLE 2 TOP PHARMA DRUGS BY SALES IN 2017 12
TABLE 3 GLOBAL THROMBOSIS DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 41
TABLE 4 OTHER PROMINENT VENDORS IN THE THROMBOSIS DRUGS MARKET 48
TABLE 5 ASPEN PHARMACARE HOLDINGS LIMITED: OFFERINGS 49
TABLE 6 ASPEN PHARMACARE HOLDINGS LIMITED: RECENT DEVELOPMENTS 49
TABLE 7 JOHNSON & JOHNSON: OFFERINGS 54
TABLE 8 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 54
TABLE 9 SANOFI S.A.: PRODUCT OFFERINGS 61
TABLE 10 SANOFI S.A.: RECENT DEVELOPMENTS 61
TABLE 11 BOEHRINGER INGELHEIM GMBH: PRODUCT OFFERINGS 67
TABLE 12 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 67
TABLE 13 BAYER AG: PRODUCT OFFERINGS 73
TABLE 14 BAYER AG: RECENT DEVELOPMENTS 73
TABLE 15 BRISTOL–MYERS SQUIBB: OFFERINGS 79
TABLE 16 BRISTOL–MYERS SQUIBB: RECENT DEVELOPMENTS 79
TABLE 17 ASTRAZENECA PLC: SNAPSHOT 85
TABLE 18 ASTRAZENECA PLC: RECENT DEVELOPMENTS 85
TABLE 19 PFIZER INC.: SNAPSHOT 87
TABLE 20 PFIZER INC.: RECENT DEVELOPMENTS 87
TABLE 21 BAXTER INTERNATIONAL INC.: SNAPSHOT 89
TABLE 22 BAXTER INTERNATIONAL INC.: RECENT DEVELOPMENTS 89
TABLE 23 DAIICHI SANKYO: SNAPSHOT 91
TABLE 24 DAIICHI SANKYO: RECENT DEVELOPMENTS 91

List of Charts

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010–2016) 10
CHART 2 PHARMACEUTICAL MOLECULES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS) 11
CHART 3 R&D INVESTMENTS BY TOP 10 COMPANIES 12
CHART 4 PHARMACEUTICAL DRUGS BY SALES, 2017 ($BILLION) 13
CHART 5 RESEARCH METHODOLOGY OF GLOBAL THROMBOSIS DRUGS MARKET 16
CHART 6 GLOBAL THROMBOSIS DRUGS MARKET REVENUE, 2017–2024 ($MILLION) 20
CHART 7 SEGMENTATION OF GLOBAL THROMBOSIS DRUGS MARKET 24
CHART 8 PEST ANALYSIS OF GLOBAL THROMBOSIS DRUGS MARKET 24
CHART 9 PORTER 5 FORCES ON GLOBAL THROMBOSIS DRUGS MARKET 25
CHART 10 MARKET DYNAMICS: DRO ANALYSIS 27
CHART 11 DRO – IMPACT ANALYSIS OF GLOBAL THROMBOSIS DRUGS MARKET 30
CHART 12 KEY STAKEHOLDERS 31
CHART 13 GLOBAL THROMBOSIS DRUGS MARKET SHARE BY DRUG CLASS SEGMENTATION, 2017 (%) 33
CHART 14 GLOBAL THROMBOSIS DRUGS MARKET SHARE BY DRUG CLASS SEGMENTATION, 2024 (%) 33
CHART 15 GLOBAL FACTOR XA INHIBITORS MARKET FORECAST, 2017–2024 ($MILLION) 34
CHART 16 GLOBAL LOW MOLECULAR WEIGHT HEPARIN MARKET FORECAST, 2017–2024 ($MILLION) 35
CHART 17 GLOBAL P2Y12 PLATELET INHIBITORS MARKET FORECAST, 2017–2024 ($MILLION) 36
CHART 18 GLOBAL THROMBOSIS DRUGS MARKET SHARE BY INDICATION SEGMENTATION, 2017 (%) 38
CHART 19 GLOBAL THROMBOSIS DRUGS MARKET SHARE BY GEOGRAPHICAL SEGMENTATION, 2017 (%) 40
CHART 20 GLOBAL THROMBOSIS DRUGS MARKET SHARE BY GEOGRAPHICAL SEGMENTATION, 2024 (%) 40
CHART 21 THROMBOSIS DRUGS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION) 42
CHART 22 THROMBOSIS DRUGS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION) 43
CHART 23 THROMBOSIS DRUGS MARKET REVENUE IN ASIA PACIFIC, 2017–2024 ($MILLION) 45
CHART 24 THROMBOSIS DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION) 45
CHART 25 ASPEN PHARMACARE HOLDINGS LIMITED: OVERVIEW SNAPSHOT 49
CHART 26 ASPEN PHARMACARE HOLDINGS LIMITED: BUSINESS UNITS 50
CHART 27 ASPEN PHARMACARE HOLDINGS LIMITED: GEOGRAPHIC PRESENCE 51
CHART 28 ASPEN PHARMACARE HOLDINGS LIMITED: SWOT ANALYSIS 52
CHART 29 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 56
CHART 30 JOHNSON & JOHNSON: BUSINESS UNITS 57
CHART 31 JOHNSON & JOHNSON: GEOGRAPHIC PRESENCE 58
CHART 32 JOHNSON & JOHNSON: SWOT ANALYSIS 60
CHART 33 SANOFI S.A.: OVERVIEW SNAPSHOT 63
CHART 34 SANOFI S.A.: BUSINESS UNITS 64
CHART 35 SANOFI S.A.: GEOGRAPHIC PRESENCE 65
CHART 36 SANOFI S.A.: SWOT ANALYSIS 66
CHART 37 BOEHRINGER INGELHEIM GMBH: OVERVIEW SNAPSHOT 68
CHART 38 BOEHRINGER INGELHEIM GMBH: BUSINESS UNITS 69
CHART 39 BOEHRINGER INGELHEIM GMBH: GEOGRAPHIC PRESENCE 70
CHART 40 BOEHRINGER INGELHEIM GMBH: SWOT ANALYSIS 71
CHART 41 BAYER AG: OVERVIEW SNAPSHOT 74
CHART 42 BAYER AG: BUSINESS UNITS 75
CHART 43 BAYER AG: GEOGRAPHIC PRESENCE 76
CHART 44 BAYER AG: SWOT ANALYSIS 77
CHART 45 BRISTOL–MYERS SQUIBB: OVERVIEW SNAPSHOT 81
CHART 46 BRISTOL–MYERS SQUIBB: BUSINESS UNITS 82
CHART 47 BRISTOL–MYERS SQUIBB: GEOGRAPHIC PRESENCE 83
CHART 48 BRISTOL–MYERS SQUIBB: SWOT ANALYSIS 83